

PRESS RELEASE  
8 November 2011



## **BioInvent holds Capital Markets Day in Stockholm**

### ***Detailed review of BioInvent's programmes, including its lead products, BI-204 (cardiovascular disease) and TB-402 (anti-Factor VIII)***

**Lund, Sweden–8 November 2011** – BioInvent International AB (OMXS: BINV) will hold its first Capital Markets Day for investors, analysts and media today.

The event will be hosted by Svein Mathisen, CEO, and Sten Westerberg, VP IR of BioInvent. They will be supported by members of the senior team, including Steven Glazer MD, Senior Vice President, Development, Martin Wiles, Senior Vice President, Business Development, Björn Frenhéus, Vice President, Preclinical Research and Kristina Berggren, Project Manager BI-204.

The Company is pleased to announce that three of the presentations will be given by external speakers. Speaking about cardiovascular imaging technologies and clinical overview in Acute Coronary Syndrome will be Ahmed Tawakol MD, of the Massachusetts General Hospital, Harvard Medical School, Boston, US. Providing a clinical overview of anti-thrombotic treatments will be Peter Verhamme MD, Department of Vascular Medicine and Haemostasis, University of Leuven. There will also be a talk on how antibodies have transformed drug development by Carl Borrebaeck, co-founder and non-executive director of BioInvent, and professor of Immunotechnology at Lund University.

The meeting will primarily focus on BioInvent's clinical portfolio. The main sessions will focus on BI-204, which is targeting cardiovascular disease, and on TB-402, which is targeting the human blood clotting factor, Factor VIII and is being developed as an anti-coagulant to prevent deep vein thrombosis in patients undergoing orthopaedic surgery and in certain medical patients. A summary of BioInvent's other clinical and preclinical activities is being provided in the afternoon. A full programme of the day can be found on the BioInvent website, [www.bioinvent.com](http://www.bioinvent.com).

The event will take place in Wallenbergsalen, Kungl. Ingenjörsvetenskapsakademien (IVA), Grev Turegatan 16, Stockholm, and presentations will start from 8:30am to 2pm CET.

For those unable to attend in person, a webcast of the event will be available on the BioInvent website.

### **Notes to Editors:**

#### **About BioInvent**

BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company currently has four clinical development projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances to strengthen the product pipeline and increase the likelihood of success. These partners include Genentech, Human Genome Sciences, Roche and ThromboGenics.

The company's competitive position is underpinned by an in substance patented antibody development platform. The scope and strength of this platform is also utilised by partners, such as Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe, UCB and XOMA. More information is available at [www.bioinvent.com](http://www.bioinvent.com).

**For further information, please contact:**

***BioInvent International AB***

Svein Mathisen  
President & CEO  
Tel: +46 (0)46-286 85 67  
Mobile: +46 (0)708-97 82 13  
E-mail: [svein.mathisen@bioinvent.com](mailto:svein.mathisen@bioinvent.com)

Sten Westerberg  
Vice President, Investor Relations  
Tel: +46 (0)46-286 85 52  
Mobile: +46 (0)768-68 50 09  
E-mail: [sten.westerberg@bioinvent.com](mailto:sten.westerberg@bioinvent.com)

College Hill (media enquiries)  
Melanie Toyne Sewell, Anastasios Koutsos  
Tel: +44 (0)20 7866 7856  
Rebecca Skye Dietrich  
Tel: -1 (857) 241-0795  
E-mail: [bioinvent@collegehill.com](mailto:bioinvent@collegehill.com)

**BioInvent International AB (publ)**

Co. reg. No. 556537-7263,  
Address: Sölvegatan 41  
Mailing address: SE-223 70 LUND  
Tel: +46 (0)46 286 85 50  
[info@bioinvent.com](mailto:info@bioinvent.com)  
[www.bioinvent.com](http://www.bioinvent.com)

*Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.00 a.m. CET, on 8 November, 2011.*